

CSD/BSE&NSE/PR/2025-26
August 12, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001
Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Press Release

We enclose herewith press release viz. “Cohance Lifesciences Announces ₹230 mn Investment and Progress on cGMP Oligonucleotide Facility at Hyderabad, India”.

This is for your information and record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Encl: as above

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad
Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road,
Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com





Cohance Lifesciences Announces ₹230 mn Investment and Progress on cGMP Oligonucleotide Facility at Hyderabad, India

- New facility at Hyderabad to provide up to 700 kg annual GMP capacity for complex oligonucleotide building blocks
- Builds on Cohance's core strengths in modified nucleosides and locked nucleic acids (LNA), enabling scale-up from R&D to commercial supply
- Aligned with our long-term strategy, this investment advances Cohance's global expansion plan in niche technology-led modalities.

Hyderabad, India, 12th August, 2025

Cohance Lifesciences Limited ("Cohance" or "the Company"), a partner of choice for global innovator pharma companies, announced INR 230 million investment and significant progress on its new cGMP oligonucleotide building block manufacturing facility in Hyderabad, India. This strategic investment strengthens Cohance's integrated oligonucleotide platform and enhances its position as a preferred partner for emerging modalities.

Cohance brings deep expertise in modified nucleosides and locked nucleic acids (LNA), with a proven track record in complex nucleoside and nucleic acid synthesis at the R&D stage. The new facility will enable the Company to take these high-value chemistries from laboratory scale to **full commercial manufacturing**, meeting the needs of innovators advancing oligonucleotide-based therapeutics.

Integrated with pilot plant for early-stage synthesis and for non-GMP scale-up, the facility will add fit-for-purpose GMP capacity of up to 700 kg annually, with room for future expansion. This scale, combined with advanced environmental controls including ISO Class 8 clean rooms and RH-controlled areas, is designed to meet the stringent requirements of complex oligonucleotide building block production.

Customer engagements are already underway, with audits planned in the coming quarters. Kilo lab validations and modified nucleotides are in progress, with GMP-grade PMO and LNA amidite validations expected to commence in CY26.

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com

Vivek Sharma, Executive Chairman, Cohance Lifesciences, said: *“Oligonucleotides are a fast-emerging therapeutic class, and innovators are seeking integrated, cost-efficient partners with scalable GMP capacity. This facility is a high-impact strategic investment that complements our pilot and scale-up assets, positioning Cohance to deliver with speed, quality, and flexibility while expanding our role in next-generation therapeutics.”*

This investment follows the Company’s recently announced USD 10 million expansion of cGMP bioconjugation capabilities at NJ Bio in the United States. Together, these investments form part of Cohance’s planned capacity expansion program across high-growth modalities, enhancing its ability to serve global innovators from early development to commercial supply.

About Cohance Lifesciences

Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. Leveraging a combined platform with state-of-the-art facilities in India and the U.S., Cohance delivers integrated solutions from early development to commercial supply for leading global pharma companies. In FY25, revenue was INR 26 billion (~USD 313 million) with 33.6% adjusted EBITDA margins, with the CDMO business—driven largely by its commercial partnerships with global innovators.

-ENDS-

For more information, please contact:

Cyndrella Carvalho, Head - Investor Relations,

Cohance Lifesciences Limited

Tel: 040 2354 3311

Email: cyndrella.carvalho@cohance.com

Gavin Desa / Rishab Barar

CDR India

Tel: +91 98206 37649/ +91 77770 35061

Email: gavin@cdr-india.com
rishab@cdr-india.com

Cohance Lifesciences Limited

(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com